1. Home
  2. NAVI vs KURA Comparison

NAVI vs KURA Comparison

Compare NAVI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navient Corporation

NAVI

Navient Corporation

HOLD

Current Price

$8.83

Market Cap

760.4M

Sector

Finance

ML Signal

HOLD

Logo Kura Oncology Inc.

KURA

Kura Oncology Inc.

HOLD

Current Price

$9.19

Market Cap

841.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAVI
KURA
Founded
1973
2014
Country
United States
United States
Employees
670
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
760.4M
841.6M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NAVI
KURA
Price
$8.83
$9.19
Analyst Decision
Sell
Buy
Analyst Count
6
11
Target Price
$10.00
$25.56
AVG Volume (30 Days)
765.9K
1.4M
Earning Date
04-29-2026
05-12-2026
Dividend Yield
6.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$67,482,000.00
Revenue This Year
$76.23
$28.28
Revenue Next Year
$15.73
$106.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.24
52 Week Low
$7.33
$5.45
52 Week High
$13.87
$12.49

Technical Indicators

Market Signals
Indicator
NAVI
KURA
Relative Strength Index (RSI) 57.61 35.98
Support Level $7.86 $9.08
Resistance Level $8.82 $9.82
Average True Range (ATR) 0.27 0.50
MACD 0.00 -0.25
Stochastic Oscillator 88.49 11.79

Price Performance

Historical Comparison
NAVI
KURA

About NAVI Navient Corporation

Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.

About KURA Kura Oncology Inc.

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Share on Social Networks: